Login to Your Account

'Can't Make 42,000 Drugs'

Arrowhead Buys Alvos, Signs Up (First) Partner Four Months Later

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, August 20, 2012

In April, Arrowhead Research Corp. bought Alvos Therapeutics Inc. in an all-stock deal valued at about $2.1 million plus additional stock worth up to $23.5 million based on the achievement of clinical and regulatory milestones.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription